Anuh Pharma profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Returns
12.1%12.1%14.5%
7.7%7.7%9.4%
14.8%14.8%15.9%
13.1%12.7%15.4%
Margins
8.3%8.0%9.2%
6.5%6.5%7.9%
—−1.7%—
7.7%7.0%9.2%
5.7%5.3%7.2%
−1.4%−1.4%2.6%
Additional
26.6%24.3%22.4%
—36.5%26.4%
12.1%7.7%10.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ANUHPHR₹79.74

Anuh Pharma Limited

· Pharma & Health
₹ CrorePeersAHCLWANBURYZIMLABBAJAJHCARETHEMISMEDLINCOLNVALIANTLABSIGACHIMcap ₹799 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity14.5212.1012.10
Return on Assets9.357.727.72
Return on Capital Employed15.9014.7514.75
Return on Invested Capital15.3912.7313.13
Margins
EBITDA Margin9.218.008.32
Operating Margin7.896.526.52
Incremental Operating Margin—-1.66—
Pretax Margin9.227.037.73
Net Income Margin7.165.325.67
FCF Margin2.59-1.41-1.41
Additional
Effective Tax Rate22.3824.3026.62
Dvd Payout Ratio26.4436.47—
Sustainable Growth Rate10.687.6912.10
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.